May 1, 2018

**Update: Commonwealth Diagnostics International, Inc. Re-Launches IBSchek™ At Digestive Disease Week® (DDW) June 2018**

First Clinically Validated Blood Test for Diagnosing Diarrhea-Predominant and Mixed-Type Irritable Bowel Syndrome

SALEM, MA May 1, 2018 - Commonwealth Diagnostics International (CDI), Inc., an international diagnostic service provider specializing in functional gastrointestinal disorders, recently announced the commercial re-launch of IBSchek™, the first clinically validated blood test for diarrhea-predominant and mixed-type Irritable Bowel Syndrome (IBS-D, IBS-M). CDI will officially re-launch IBSchek to the gastroenterology community at Digestive Disease Week in Washington, DC in June 2018. CDI is a registered exhibitor at the Walter E. Washington Convention Center, Booth #919.

IBSchek is a simple blood test that identifies the presence of two antibodies, anti-CdtB and anti-vinculin, which data have shown to be indicative of diarrhea-predominant IBS (IBS-D) and mixed-type IBS (IBS-M). As a part of the re-launch, CDI has announced that the IBSchek key biomarkers, anti-CdtB and anti-vinculin, are now included in the Rome Foundation’s official Rome IV Clinical Decision Toolkit. Additionally, CDI continues to work with its medical advisory board, key opinion leaders, and leading healthcare institutions around the globe to conduct revalidation studies and clinical research projects aimed at further enhancing the clinical application and utility of these important biomarkers. CDI is also in the process of continuing to establish new commercial partnerships and distribution networks to assist in the expansion and scale of IBSchek in the United States.

“We are excited to announce the availability of IBSchek, and to continue to play our part in assisting the GI community to better-identify and treat the significant portion of the US and global population of IBS suffers searching for a diagnosis,” said Craig S. Strasnick, President and CEO at CDI. “At CDI, we view new solutions such as IBSchek as a representation of our unwavering commitment and dedication to providing innovative and cost-effective solutions to debilitating functional GI illness for our healthcare providers and their patients in the United States and around the world.”

In addition to the re-launch of IBSchek, Commonwealth Diagnostics is also proud to announce the expansion of their test menu to include a serum-based ELISA test panel for Celiac Disease, which includes anti-human Tissue Transglutaminase (tTG) and deamidated gliadin peptide (DGP) IgA and IgG antibodies. This test is a valuable addition to the test portfolio due to the similar symptomology between Celiac and IBS patients, especially in the IBS subtypes of diarrhea predominant and mixed symptoms. “We believe that using both IBSchek and the CDI Celiac Panel together will further direct clinicians towards the potential cause of their patients’ symptoms, which may ultimately lead to a more effective course of treatment through a clearer diagnosis,” said Brianna Cassidy, PhD, Chief Science Officer at CDI. CDI will begin accepting diagnostic samples for Celiac testing in June 2018.

For more information about CDI, please visit our website at [www.CommDx.com](http://www.CommDx.com), or contact our customer service department at 888-258-5966.
**References:**


